Limits...
Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice

View Article: PubMed Central - PubMed

ABSTRACT

Purpose: The aim of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF), fixed-combination (FC) bimatoprost 0.03%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension in a clinical practice setting.

Patients and methods: This open-label study observed patients switched to PF FC bimatoprost 0.03%/timolol 0.5% due to insufficient intraocular pressure (IOP) control on previous therapies. IOP was measured at baseline and at ~12 weeks. Tolerability and continuation of therapy were also assessed.

Results: A total of 1,553 patients were included in the study, and the per-protocol population comprised 1,391 patients. There were some minor deviations from protocol: some patients with no prior therapy and some who switched for reasons other than insufficient IOP control were included in the analysis. The mean IOP was reduced by 27.4%, from 22.2 mmHg to 16.1 mmHg. In subgroup analyses, the mean IOP was significantly reduced from baseline, irrespective of whether previous treatment was monotherapy or combination therapy, and preserved or PF therapy. Physicians mostly (88.1%) reported the IOP-lowering efficacy of PF FC bimatoprost 0.03%/timolol 0.5% to be as expected or better than expected. Switching to PF FC bimatoprost 0.03%/timolol 0.5% resulted in reductions from baseline in the number of patients reporting ocular symptoms. Adverse events were reported by 6.2% of patients, the most common being eye irritation (1.6%) and eye pruritus (1.0%). Physicians reported treatment compliance as better or unchanged compared with prior treatment in almost all patients (93.9%). Most patients were expected to continue PF FC bimatoprost 0.03%/timolol 0.5% after the end of the study.

Conclusion: Switching to PF FC bimatoprost 0.03%/timolol 0.5% was associated with significant IOP reductions from baseline over 12 weeks. Adverse events were uncommon, and compliance was high compared with previous therapy. PF FC bimatoprost 0.03%/timolol 0.5% may be a suitable treatment for patients with inadequately controlled IOP or who are sensitive to preservatives.

No MeSH data available.


Percentage of patients on previous intraocular pressure-lowering treatment taking different numbers of therapies.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5036566&req=5

f2-opth-10-1837: Percentage of patients on previous intraocular pressure-lowering treatment taking different numbers of therapies.

Mentions: Most patients (97.2%) were previously treated with an IOP-lowering therapy. Of those patients previously treated, the majority (73.7%) had been prescribed a preservative-containing IOP-lowering therapy and 16.2% had received prior PF therapy; data on this aspect were missing for 10.1%. Prior therapies reported in ≥5% of patients are shown in Figure 1. Latanoprost and timolol were the most frequent prior therapies. In total, 54.1% of patients taking therapy prior to the study were on a monotherapy regimen; however, 24.4% of patients were taking two therapies, and 21.5% of patients were taking three or more therapies (Figure 2). Insufficient IOP control on earlier IOP-lowering therapy was the main reason for switching to PF FC bimatoprost 0.03%/timolol 0.5% from a prior IOP-lowering therapy in 83.1% of patients (Table 2).


Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
Percentage of patients on previous intraocular pressure-lowering treatment taking different numbers of therapies.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5036566&req=5

f2-opth-10-1837: Percentage of patients on previous intraocular pressure-lowering treatment taking different numbers of therapies.
Mentions: Most patients (97.2%) were previously treated with an IOP-lowering therapy. Of those patients previously treated, the majority (73.7%) had been prescribed a preservative-containing IOP-lowering therapy and 16.2% had received prior PF therapy; data on this aspect were missing for 10.1%. Prior therapies reported in ≥5% of patients are shown in Figure 1. Latanoprost and timolol were the most frequent prior therapies. In total, 54.1% of patients taking therapy prior to the study were on a monotherapy regimen; however, 24.4% of patients were taking two therapies, and 21.5% of patients were taking three or more therapies (Figure 2). Insufficient IOP control on earlier IOP-lowering therapy was the main reason for switching to PF FC bimatoprost 0.03%/timolol 0.5% from a prior IOP-lowering therapy in 83.1% of patients (Table 2).

View Article: PubMed Central - PubMed

ABSTRACT

Purpose: The aim of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF), fixed-combination (FC) bimatoprost 0.03%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension in a clinical practice setting.

Patients and methods: This open-label study observed patients switched to PF FC bimatoprost 0.03%/timolol 0.5% due to insufficient intraocular pressure (IOP) control on previous therapies. IOP was measured at baseline and at ~12 weeks. Tolerability and continuation of therapy were also assessed.

Results: A total of 1,553 patients were included in the study, and the per-protocol population comprised 1,391 patients. There were some minor deviations from protocol: some patients with no prior therapy and some who switched for reasons other than insufficient IOP control were included in the analysis. The mean IOP was reduced by 27.4%, from 22.2 mmHg to 16.1 mmHg. In subgroup analyses, the mean IOP was significantly reduced from baseline, irrespective of whether previous treatment was monotherapy or combination therapy, and preserved or PF therapy. Physicians mostly (88.1%) reported the IOP-lowering efficacy of PF FC bimatoprost 0.03%/timolol 0.5% to be as expected or better than expected. Switching to PF FC bimatoprost 0.03%/timolol 0.5% resulted in reductions from baseline in the number of patients reporting ocular symptoms. Adverse events were reported by 6.2% of patients, the most common being eye irritation (1.6%) and eye pruritus (1.0%). Physicians reported treatment compliance as better or unchanged compared with prior treatment in almost all patients (93.9%). Most patients were expected to continue PF FC bimatoprost 0.03%/timolol 0.5% after the end of the study.

Conclusion: Switching to PF FC bimatoprost 0.03%/timolol 0.5% was associated with significant IOP reductions from baseline over 12 weeks. Adverse events were uncommon, and compliance was high compared with previous therapy. PF FC bimatoprost 0.03%/timolol 0.5% may be a suitable treatment for patients with inadequately controlled IOP or who are sensitive to preservatives.

No MeSH data available.